HIV vaccine candidates generate in vitro T cell response to putative epitopes in Chinese-origin rhesus macaques

Vaccine

Volumn 30, Issue 9, 2012, Pages 1601-1608

  Liao, Qi ^a   Strong, Amie J ^b   Liu, Ying ^c   Liu, Yanhou ^a   Meng, Peng ^a   Fu, Yang ^a   Touzjian, Neal ^b   Shao, Yiming ^c   Zhao, Zhongfang ^a   Lu, Yichen ^b,d  

^a NANKAI UNIVERSITY   (China)

^b Vaccine Technologies Inc   (United States)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Chinese rhesus monkey; Epitope; HIV; MHC; Vaccine

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 1; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHINESE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSPOT ASSAY; GENE FREQUENCY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE;

AIDS VACCINES; ANIMALS; DISEASE MODELS, ANIMAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPES; HIV CORE PROTEIN P24; HIV INFECTIONS; HLA-B ANTIGENS; MACACA MULATTA; PEPTIDE LIBRARY; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; VACCINES, DNA;

EID: 84862779354     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.117     Document Type: Article

References (50)

1. Cohen J. AIDS research. Vaccine studies stymied by shortage of animals. Science 2000, 287(5455):959-960.
2. Hernandez R.D., Hubisz M.J., Wheeler D.A., Smith D.G., Ferguson B., Rogers J., et al. Demographic histories and patterns of linkage disequilibrium in Chinese and Indian rhesus macaques. Science 2007, 316(5822):240-243.
3. Ling B., Veazey R.S., Luckay A., Penedo C., Xu K., Lifson J.D., et al. SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans. AIDS 2002, 16(11):1489-1496.
4. Joag S.V., Stephens E.B., Adams R.J., Foresman L., Narayan O. Pathogenesis of SIVmac infection in Chinese and Indian rhesus macaques: effects of splenectomy on virus burden. Virology 1994, 200(2):436-446.
5. Trichel A.M., Rajakumar P.A., Murphey-Corb M. Species-specific variation in SIV disease progression between Chinese and Indian subspecies of rhesus macaque. J Med Primatol 2002, 31(4-5):171-178.
6. Ling B., Veazey R.S., Penedo C., Xu K., Lifson J.D., Marx P.A. Longitudinal follow up of SIVmac pathogenesis in rhesus macaques of Chinese origin: emergence of B cell lymphoma. J Med Primatol 2002, 31(4-5):154-163.
7. Reimann K.A., Parker R.A., Seaman M.S., Beaudry K., Beddall M., Peterson L., et al. Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J Virol 2005, 79(14):8878-8885.
8. Xia H.J., Zhang G.H., Ma J.P., Dai Z.X., Li S.Y., Han J.B., et al. Dendritic cell subsets dynamics and cytokine production in SIVmac239-infected Chinese rhesus macaques. Retrovirology 2010, 7:102.
9. Monceaux V., Viollet L., Petit F., Cumont M.C., Kaufmann G.R., Aubertin A.M., et al. CD4+ CCR5+ T-cell dynamics during simian immunodeficiency virus infection of Chinese rhesus macaques. J Virol 2007, 81(24):13865-13875.
10. Degenhardt J.D., de Candia P., Chabot A., Schwartz S., Henderson L., Ling B., et al. Copy number variation of CCL3-like genes affects rate of progression to simian-AIDS in Rhesus Macaques (Macaca mulatta). PLoS Genet 2009, 5(1):e1000346.
11. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283(5403):857-860.
12. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998, 279(5359):2103-2106.
13. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68(7):4650-4655.
14. Mothe B.R., Weinfurter J., Wang C., Rehrauer W., Wilson N., Allen T.M., et al. Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 2003, 77(4):2736-2740.
15. Zhang Z.Q., Fu T.M., Casimiro D.R., Davies M.E., Liang X., Schleif W.A., et al. Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J Virol 2002, 76(24):12845-12854.
16. Goulder P.J., Watkins D.I. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 2008, 8(8):619-630.
17. Solomon C., Southwood S., Hoof I., Rudersdorf R., Peters B., Sidney J., et al. The most common Chinese rhesus macaque MHC class I molecule shares peptide binding repertoire with the HLA-B7 supertype. Immunogenetics 2010, 62(7):451-464.
18. Huang X., Liu L., Ren L., Qiu C., Wan Y., Xu J. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses. Vaccine 2007, 25(52):8874-8884.
19. Huang X., Xu J., Qiu C., Ren L., Liu L., Wan Y., et al. Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses. Vaccine 2007, 25(14):2620-2629.
20. Cao H., Agrawal D., Kushner N., Touzjian N., Essex M., Lu Y. Delivery of exogenous protein antigens to major histocompatibility complex class I pathway in cytosol. J Infect Dis 2002, 185(2):244-251.
21. Kushner N., Zhang D., Touzjian N., Essex M., Lieberman J., Lu Y. A fragment of anthrax lethal factor delivers proteins to the cytosol without requiring protective antigen. Proc Natl Acad Sci USA 2003, 100(11):6652-6657.
22. Lu Y., Friedman R., Kushner N., Doling A., Thomas L., Touzjian N., et al. Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity. Proc Natl Acad Sci USA 2000, 97(14):8027-8032.
23. Ballard J.D., Doling A.M., Beauregard K., Collier R.J., Starnbach M.N. Anthrax toxin-mediated delivery in vivo and in vitro of a cytotoxic T-lymphocyte epitope from ovalbumin. Infect Immun 1998, 66(2):615-619.
24. Loffredo J.T., Maxwell J., Qi Y., Glidden C.E., Borchardt G.J., Soma T., et al. Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol 2007, 81(16):8827-8832.
25. Kaizu M., Borchardt G.J., Glidden C.E., Fisk D.L., Loffredo J.T., Watkins D.I., et al. Molecular typing of major histocompatibility complex class I alleles in the Indian rhesus macaque which restrict SIV CD8+ T cell epitopes. Immunogenetics 2007, 59(9):693-703.
26. Lu Y., Salvato M.S., Pauza C.D., Li J., Sodroski J., Manson K., et al. Utility of SHIV for testing HIV-1 vaccine candidates in macaques. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 12(2):99-106.
27. Shu L., Touzjian N., Nan D., Kushner N., Strong A.J., Zeping W., et al. Recombinant hepatitis B large surface antigen, successfully produced in Escherichia coli, stimulates T-cell response in mice. Vaccine 2006, 24(20):4409-4416.
28. Anthony D.D., Lehmann P.V. T-cell epitope mapping using the ELISPOT approach. Methods 2003, 29(3):260-269.
29. Gibbs R.A., Rogers J., Katze M.G., Bumgarner R., Weinstock G.M., Mardis E.R., et al. Evolutionary and biomedical insights from the rhesus macaque genome. Science 2007, 316(5822):222-234.
30. Shedlock D.J., Silvestri G., Weiner D.B. Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol 2009, 9(10):717-728.
31. Wang W., Cong Z., Liu X., Tong W., Qiao H., Jiang H., et al. Frequency of the major histocompatibility complex Mamu-A*01 allele in experimental rhesus macaques in China. J Med Primatol 2010, 374-380.
32. Otting N., de Vos-Rouweler A.J., Heijmans C.M., de Groot N.G., Doxiadis G.G., Bontrop R.E. MHC class I A region diversity and polymorphism in macaque species. Immunogenetics 2007, 59(5):367-375.
33. Karl J.A., Wiseman R.W., Campbell K.J., Blasky A.J., Hughes A.L., Ferguson B., et al. Identification of MHC class I sequences in Chinese-origin rhesus macaques. Immunogenetics 2008, 60(1):37-46.
34. Otting N., Heijmans C.M., van der Wiel M., de Groot N.G., Doxiadis G.G., Bontrop R.E. A snapshot of the Mamu-B genes and their allelic repertoire in rhesus macaques of Chinese origin. Immunogenetics 2008, 60(9):507-514.
35. Dong C., Liu L., Zhao H., Wang J., Liao Y., Zhang X., et al. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 2011, 29(37):6269-6275.
36. Qiu Y., Liu Y., Qi Z., Wang W., Kou Z., Zhang Q., et al. Comparison of immunological responses of plague vaccines F1+rV270 and EV76 in Chinese-origin rhesus macaque, Macaca mulatta. Scand J Immunol 2010, 72(5):425-433.
37. Hickman-Miller H.D., Bardet W., Gilb A., Luis A.D., Jackson K.W., Watkins D.I., et al. Rhesus macaque MHC class I molecules present HLA-B-like peptides. J Immunol 2005, 175(1):367-375.
38. Sidney J., Dzuris J.L., Newman M.J., Johnson R.P., Kaur A., Amitinder K., et al. Definition of the Mamu A*01 peptide binding specificity: application to the identification of wild-type and optimized ligands from simian immunodeficiency virus regulatory proteins. J Immunol 2000, 165(11):6387-6399.
39. Dzuris J.L., Sidney J., Appella E., Chesnut R.W., Watkins D.I., Sette A. Conserved MHC class I peptide binding motif between humans and rhesus macaques. J Immunol 2000, 164(1):283-291.
40. Madden D.R. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol 1995, 13:587-622.
41. Stryhn A., Pedersen L.O., Holm A., Buus S. Longer peptide can be accommodated in the MHC class I binding site by a protrusion mechanism. Eur J Immunol 2000, 30(11):3089-3099.
42. Horig H., Young A.C., Papadopoulos N.J., DiLorenzo T.P., Nathenson S.G. Binding of longer peptides to the H-2Kb heterodimer is restricted to peptides extended at their C Terminus: refinement of the inherent MHC Class I peptide binding criteria. J Immunol 1999, 163(8):4434-4441.
43. Karlsson R.K., Jennes W., Page-Shafer K., Nixon D.F., Shacklett B.L. Poorly soluble peptides can mimic authentic ELISPOT responses. J Immunol Methods 2004, 285(1):89-92.
44. Goulder P.J., Brander C., Tang Y., Tremblay C., Colbert R.A., Addo M.M., et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001, 412(6844):334-338.
45. Johnson R., Trocha A., Yang L., Mazzara G., Panicali D., Buchanan T., et al. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J Immunol 1991, 147(5):1512-1521.
46. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007, 13(1):46-53.
47. Sipsas N.V., Kalams S.A., Trocha A., He S., Blattner W.A., Walker B.D., et al. Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1. J Clin Invest 1997, 99(4):752-762.
48. Altfeld M., Kalife E.T., Qi Y., Streeck H., Lichterfeld M., Johnston M.N., et al. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8+ T cell response against HIV-1. PLoS Med 2006, 3(10):e403.
49. Tomiyama H., Sakaguchi T., Miwa K., Oka S., Iwamoto A., Kaneko Y., et al. Identification of multiple HIV-1 CTL epitopes presented by HLA-B*5101 molecules. Hum Immunol 1999, 60(3):177-186.
50. Kaul R., Dong T., Plummer F.A., Kimani J., Rostron T., Kiama P., et al. CD8+ lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 2001, 107(10):1303-1310.